FILTER

LATEST INTERVIEWS

Mining
Chile

Darío Barros Izquierdo

GENERAL MANAGER, ECHEVERRIA IZQUIERDO MONTAJES INDUSTRIALES
Chile Mining 2021 - Digital Interactive
"The challenge for the construction sector is to not overreact to any situation and also take a longer-term view, using this time as an opportunity to be creative and innovative, incorporate new technology and be more productive and sustainable."
United States
Pharma & Life Sciences

Donna LaVoie

PRESIDENT & CEO, LAVOIEHEALTHSCIENCE
LaVoie Health Science explains how the communication requirements for Biotech companies have evolved significantly.
Mining
Peru

Gianflavio Carozzi

CEO, AESA
AESA speaks to GBR about how the pandemic has changed the paradigms for underground miners in Peru.
Mining
Peru

Greg Jackson

MANAGING DIRECTOR, BYRNECUT OFFSHORE
Byrnecut speaks to GBR about its expansion in the Americas.
Mining
Canada

Simon Irish

CEO, TERRESTRIAL ENERGY
Terrestrial Energy explains to GBR why small nuclear plants can benefit large mines.
Mining
Canada

Eric Lannegrace

MANAGING DIRECTOR & FOUNDER, MINERA ENVIRONMENTAL SOLUTIONS
Minera Solutions explains how solutions related to water issues are becoming increasingly important for Canada’s mines.
Mining
Canada

Paul Bradette

EXECUTIVE DIRECTOR, MINECONNECT
MineConnect explains how Northern Ontario’s mine services companies are expanding their international reach.
Petrochemicals & Chemicals
Singapore

Peter Wheeler

GENERAL MANAGER OPERATIONS (APAC), BUCKMAN
Buckman speaks to GBR of sustainable and connected chemistry.
United States
Pharma & Life Sciences

Jeff Reingold

COO, CONTRACT PHARMACAL CORP
Contract Pharmacal Corp explains how it is intends to maintain its organic growth.
Mining
Canada

Terry Harbort

PRESIDENT & CEO, TALISKER RESOURCES
Talisker Resources updates GBR on its exploration projects and explains what makes a good exploration program.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL